{"id":{"repo_id":"duquesne","oai_identifier":"oai:dsc.duq.edu:etd-2526"},"canonical_url":"https://search.ndltd.org/etd/duquesne/oai:dsc.duq.edu:etd-2526","repository":{"repo_id":"duquesne","name":"Duquesne","base_url":"https://dsc.duq.edu/do/oai/"},"display":{"title":"Development and Evaluation of Fixed Dose Combination Orally Disintegrating Tablets of Antiretroviral Drugs for Pediatrics","abstract":"The thesis work entails a bench-to-bedside translational research approach to the development of pediatric fixed dose combination of zidovudine/lamivudine/nevirapine (60/30/50mg) orally disintegrating tablets. A simple and cost-effective, direct compression method was used. Preformulation studies that included analytical and bio-analytical assay development, excipient selection and characterization of drug-excipient interaction for initial formulation were conducted. Response surface methodology was utilized to optimize the formulation in terms of disintegration time and crushing strength. Stable ODT tablet was developed with desired friability (< 1%), reasonable crushing strength, disintegration time (< 30sec) and other quality attributes such as potency and dissolution. An open label randomized two-way cross-over bioequivalence of the product (with approved IRBs), conducted in 24 healthy adult volunteers, indicated the product to be bioequivalent with the innovators. 90% C.I of the point estimates of PK parameters evaluated were in the range of 80-125% as specified by FDA.","abstract_html":"The thesis work entails a bench-to-bedside translational research approach to the development of pediatric fixed dose combination of zidovudine/lamivudine/nevirapine (60/30/50mg) orally disintegrating tablets. A simple and cost-effective, direct compression method was used. Preformulation studies that included analytical and bio-analytical assay development, excipient selection and characterization of drug-excipient interaction for initial formulation were conducted. Response surface methodology was utilized to optimize the formulation in terms of disintegration time and crushing strength. Stable ODT tablet was developed with desired friability (&lt; 1%), reasonable crushing strength, disintegration time (&lt; 30sec) and other quality attributes such as potency and dissolution. An open label randomized two-way cross-over bioequivalence of the product (with approved IRBs), conducted in 24 healthy adult volunteers, indicated the product to be bioequivalent with the innovators. 90% C.I of the point estimates of PK parameters evaluated were in the range of 80-125% as specified by FDA.","abstract_has_math":false,"creators":["Joshi, Anjali"],"institution":null,"degree_name":"MS","degree_level":"Immediate Access","degree_discipline":"Pharmaceutics","degree_department":null,"school":null,"contributors":["Wilson Meng","Moji Adeyeye","Peter Wildfong","Aleem Gangjee"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T07:52:32Z","subjects":["Pharmaceutics","Pediatrics","Antiretroviral drugs"],"languages":["English"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://dsc.duq.edu/etd/1514","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://dsc.duq.edu/etd/1514","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://dsc.duq.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adsc.duq.edu%3Aetd-2526","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Wilson Meng","Moji Adeyeye","Peter Wildfong","Aleem Gangjee"]},{"key":"dc:creator","label":"Author","values":["Joshi, Anjali"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2023-01-05T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2013-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmaceutics"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Immediate Access"]},{"key":"thesis:degree_name","label":"Degree Name","values":["MS"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Pharmaceutics","Pediatrics","Antiretroviral drugs"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://dsc.duq.edu/etd/1514"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The thesis work entails a bench-to-bedside translational research approach to the development of pediatric fixed dose combination of zidovudine/lamivudine/nevirapine (60/30/50mg) orally disintegrating tablets. A simple and cost-effective, direct compression method was used. Preformulation studies that included analytical and bio-analytical assay development, excipient selection and characterization of drug-excipient interaction for initial formulation were conducted. Response surface methodology was utilized to optimize the formulation in terms of disintegration time and crushing strength. Stable ODT tablet was developed with desired friability (< 1%), reasonable crushing strength, disintegration time (< 30sec) and other quality attributes such as potency and dissolution. An open label randomized two-way cross-over bioequivalence of the product (with approved IRBs), conducted in 24 healthy adult volunteers, indicated the product to be bioequivalent with the innovators. 90% C.I of the point estimates of PK parameters evaluated were in the range of 80-125% as specified by FDA."]},{"key":"dc:title","label":"Title","values":["Development and Evaluation of Fixed Dose Combination Orally Disintegrating Tablets of Antiretroviral Drugs for Pediatrics"]}]}],"canonical_facts":{"dc:contributor":["Wilson Meng","Moji Adeyeye","Peter Wildfong","Aleem Gangjee"],"dc:creator":["Joshi, Anjali"],"dc:date.available":["2023-01-05T08:00:00Z"],"dc:date.created":["2013-01-01T08:00:00Z"],"dc:description.abstract":["The thesis work entails a bench-to-bedside translational research approach to the development of pediatric fixed dose combination of zidovudine/lamivudine/nevirapine (60/30/50mg) orally disintegrating tablets. A simple and cost-effective, direct compression method was used. Preformulation studies that included analytical and bio-analytical assay development, excipient selection and characterization of drug-excipient interaction for initial formulation were conducted. Response surface methodology was utilized to optimize the formulation in terms of disintegration time and crushing strength. Stable ODT tablet was developed with desired friability (< 1%), reasonable crushing strength, disintegration time (< 30sec) and other quality attributes such as potency and dissolution. An open label randomized two-way cross-over bioequivalence of the product (with approved IRBs), conducted in 24 healthy adult volunteers, indicated the product to be bioequivalent with the innovators. 90% C.I of the point estimates of PK parameters evaluated were in the range of 80-125% as specified by FDA."],"dc:identifier":["https://dsc.duq.edu/etd/1514"],"dc:language":["English"],"dc:subject":["Pharmaceutics","Pediatrics","Antiretroviral drugs"],"dc:title":["Development and Evaluation of Fixed Dose Combination Orally Disintegrating Tablets of Antiretroviral Drugs for Pediatrics"],"thesis:degree_discipline":["Pharmaceutics"],"thesis:degree_level":["Immediate Access"],"thesis:degree_name":["MS"]},"updated_at":"2026-11-19T07:52:32Z"}